Treatment Algorithms Non Small Cell Lung Cancer %E2%80%93 Molecular profiling will increasingly guide the choice of therapy

We are sorry but this premium report expired!

This market research, not available anymore on the publisher's website, was withdrawn from our database.

To get an alternative report, you can either :

  • Have a look at the list of documents hereafter
  • Launch a new search below

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

DOWNLOAD THESE REPORTS NOW!

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • by Firstword Pharma
  • Sep 2014

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. Indeed, the chronic heart failure agent is believed to represent both a significant growth drive ...

Industries: Pathology | Countries: United States

Flughafen Wien AG (FLU) - Company Capsule

Flughafen Wien AG (FLU) - Company Capsule

  • $ 75
  • Company report
  • by World Market Intelligence Ltd
  • September 2014
  • 21 pages

Synopsis World Market Intelligence's "Flughafen Wien AG (FLU) - Company Capsule" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, financial ratios, key competitors, financial analysis, recent ...

Industries: Pathology | Countries: Austria, World

Payer Insights: Hepatitis C

Payer Insights: Hepatitis C

  • $ 6 495
  • Industry report
  • by Firstword Pharma
  • September 2014

The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives. Payer Insights: Hepatitis C, based on in-depth interviews with 12 leading healthcare payers in the US, is packed with hard-hitting, candid opinions ...

Industries: Pathology | Countries: United States

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • by Frost & Sullivan
  • September 2014
  • 134 pages

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast by segment, drivers and restraints, and technology trends, along with the competitive factors and ...

Industries: Pathology | Countries: World

Post Menopausal Osteoporosis - Pipeline Review, H2 2014

Post Menopausal Osteoporosis - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • by Global Markets Direct
  • September 2014
  • 80 pages

Post Menopausal Osteoporosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Post Menopausal Osteoporosis - Pipeline Review, H2 2014', provides an overview of the Post Menopausal Osteoporosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development ...

Industries: Pathology | Countries: World, Finland, United States

Secondary Hyperparathyroidism - Pipeline Review, H2 2014

Secondary Hyperparathyroidism - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • by Global Markets Direct
  • September 2014
  • 69 pages

Secondary Hyperparathyroidism - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Secondary Hyperparathyroidism - Pipeline Review, H2 2014', provides an overview of the Secondary Hyperparathyroidism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development ...

Industries: Pathology | Countries: World

Vitiligo - Pipeline Review, H2 2014

Vitiligo - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • by Global Markets Direct
  • September 2014
  • 50 pages

Vitiligo - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Vitiligo - Pipeline Review, H2 2014', provides an overview of the Vitiligo's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at ...

Industries: Pathology | Countries: World, Singapore

Pulmonary Tuberculosis - Pipeline Review, H2 2014

Pulmonary Tuberculosis - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • by Global Markets Direct
  • September 2014
  • 63 pages

Pulmonary Tuberculosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Pulmonary Tuberculosis - Pipeline Review, H2 2014', provides an overview of the Pulmonary Tuberculosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pulmonary ...

Industries: Pathology | Countries: World

Hairy Cell Leukemia - Pipeline Review, H2 2014

Hairy Cell Leukemia - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • by Global Markets Direct
  • September 2014
  • 79 pages

Hairy Cell Leukemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Hairy Cell Leukemia - Pipeline Review, H2 2014', provides an overview of the Hairy Cell Leukemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, ...

Industries: Pathology | Countries: World

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • by Global Markets Direct
  • September 2014
  • 192 pages

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014', provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline. This report provides ...

Industries: Pathology | Countries: United States, World

24/7 Customer Service

You can call our customer service 24 hours a day / 7 days a week

  • +1 718 618 4302

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.